Spine fracture risk in women with osteoporosis is reduced by new drug, romosozumab

A new treatment has been associated with rapid and large reductions in vertebral fracture, according to a large study presented at the Annual European Congress of Rheumatology.

A total of 3,589 older women with osteoporosis were treated with romosozumab for 12 months and compared to 3,591women who were given sham treatment.

In the women receiving romosozumab, all fractures occurred in the first two months of treatment. The risk of a fracture was more than five times greater in the group of women given the sham treatment.

“These results support this new class of drug as a highly effective treatment for postmenopausal women with osteoporosis with established bone mineral density deficit who are at increased risk of fracture,” explains Prof Piet Geusens lead author. “The rapid and large reduction in clinical vertebral fracture risk is an important and highly relevant clinical outcome.”

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.